[
  {
    "objectID": "slides.html",
    "href": "slides.html",
    "title": "Meta-analysis of Prognostic Studies",
    "section": "",
    "text": "The presentation"
  },
  {
    "objectID": "slides/prognostic_model34/prognostic_model34.html#section",
    "href": "slides/prognostic_model34/prognostic_model34.html#section",
    "title": "Meta-analysis of Prognostic Studies",
    "section": "",
    "text": "Investigating heterogeneity\nMeta-regression\nAdjust the meta-analysis for study-lvel variables such as:\n\nStudy characteristics\n\nStudy design\nFollow-up time\nPredictor and outcome definitions\nCut-point for dichotomozing prognostic factor"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "time4stats",
    "section": "",
    "text": "Let’s talk about statistics\n\n2023\n\n25 jun. Comparative effectiveness and personalized medicine research using real-world data. Institute of Social and Preventive Medicine, Universitat Bern. Switzerland"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-epidemiology",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-epidemiology",
    "title": "Introductory Statistics in Clinical Research",
    "section": "What is epidemiology?",
    "text": "What is epidemiology?\nStudy the occurrence of illness and its relationship to determinants\n\nDiagnosis\nEtiology (causes)\nPrognosis\nTreatment of disease"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#the-role-of-study-design",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#the-role-of-study-design",
    "title": "Introductory Statistics in Clinical Research",
    "section": "The role of study design",
    "text": "The role of study design\n\nTheoretical design\nDesign of data collection\nDesign of data analysis"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#theoretical-design",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#theoretical-design",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Theoretical design",
    "text": "Theoretical design\nFormulating the research question in terms of\n\nDomain: target population\n\n\ne.g., Adults with relapsing–remitting multiple sclerosis\n\n\nDeterminants\n\n\ne.g., Treatment with dimethyl fumarate\n\n\nOutcome\n\n\ne.g., Impairement as measured using the Expanded Disability Status Scale"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nProspective\n\nData are yet to be collected and recorded for both outcome and determinants when the study is started\n\nRetrospective\n\nData were recorded in the past and are collected after the study is initiated\nProne to missing data\nProne to recall bias\n\nCombinations of retrospective and prospective data collection can occur."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #1: Time between collection of determinant and outcome information\n\nCross-sectional design: data on determinant and outcome are measured simultaneously\n\ne.g., a study to estimate the prevalence of relapsing-remitting multiple sclerosis at one point in time\ne.g., a study to characterize the first symptoms of multiple sclerosis in patients diagnosed with multiple sclerosis\n\nLongitudinal design: outcome variables are measured over time\n\ne.g., a randomized clinical trial to investigate the efficacy and safety of dimethyl fumarate as compared with placebo in patients with relapsing–remitting multiple sclerosis (doi: 10.1056/NEJMoa1206328)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #2: Selection of study participants\nCensus\n\nAll patients with a certain condition are followed for some time to monitor the development of the outcome\ne.g., a registry study to investigate treatment persistence and disability follow-up in consecutive patients with relapsing-remitting multiple sclerosis (doi: 10.1136/jnnp-2018-319831)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #2: Selection of study participants\nSimple random sampling\n\n\nRather than examining the entire population (census), an equally informative subgroup of the population is studied.\nEvery subject has an equal chance of being selected for the study\nDistribution of determinants in the sample will reliably reflect the distributions in the population experience from whom the sample was drawn\ne.g., a national survey to investigate health outcomes and lifestyle in people with multiple sclerosis"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #2: Selection of study participants\nSimple random sampling\n\n\nRandomly select study participants within certain strata/subgroups of the population\ne.g., a case-control study where researchers recruit incident MS cases from a registry and subsequently construct a random sample of “control” individuals who are similar to the cases but do not have MS. The two groups are then compared with respect to historical determinants (e.g., sleep duration and sleep quality)\nAnother example, randomization will be stratified based on region or disease history (treatment naïve or not), body weight (common for PK study) and other factor main potentially influence the study measurements."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-5",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-5",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #2: Selection of study participants\nNon-probability sampling\n\nStudy participants are selected based on the subjective judgement of the researcher, rather than random selection\ne.g., Randomized clinical trials that are based on convenience samples from selected hospitals, including only patients with strict characteristics"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-6",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-6",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #3: Experimental versus non-interventional (observational) research"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-7",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-7",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nIssue #3: Experimental versus non-interventional (observational) research\n\n\nThe term ‘trial’ implies an element of experimentation and a prospective approach in the collection of data, whereas a ‘study’ is a systematic assessment of events that unfold without interfering with their course.\nA non-interventional trial may be interpreted as “a study where the medicinal product(s) is (are) prescribed independent to inclusion of the patient in the study and as part of a therapeutic strategy, including diagnostic and monitoring procedures, which is not decided in advance by a study protocol but is applied according to the current clinical practice”\n\n\n\nSource: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP considerations on the definition of non-interventional trials under the current legislative framework [ref]"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-8",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-8",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nExamples of non-interventional studies\n\n\nA cross-sectional study to characterize the first symptoms of MS\nA survey to investigate health outcomes in people with MS\nA post-authorization safety study (PASS) to assess to evaluate the safety and benefit-risk profile of natulizumab as prescribed in routine clinical practice\nA drug utilization study (DUS) using registry data to investigate patterns of the usage of medicines in routine clinical practice\nA registry study to investigate treatment persistence and disability follow-up in consecutive patients with relapsing-remitting multiple sclerosis (doi: 10.1136/jnnp-2018-319831)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-9",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#design-of-data-collection-9",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Design of Data Collection",
    "text": "Design of Data Collection\nExamples of experimental clinical trials\n\nA phase III clinical trial to investigate the efficacy and safety of dimethyl fumarate as compared with placebo in patients with relapsing–remitting multiple sclerosis (doi: 10.1056/NEJMoa1206328)\nA single-arm study where all participants are assigned to receive the experimental intervention after which their results are compared to the patient’s history"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#common-study-designs",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#common-study-designs",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Common study designs",
    "text": "Common study designs\n\n\nNIS: Non-interventional study; EXP: experimental study"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#background",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#background",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Background",
    "text": "Background\nKey characteristics\n\nProspective experiment of medical intervention(s)\nAim is to measure the intervention effect on prognosis\nExposure groups differ only by intervention(s) of interest\nPatients are allocated to the intervention, do not choose it"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#background-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#background-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Background",
    "text": "Background\nKey design features\n\nInclusion and exclusion criteria\nControl group\nRandomisation\nBlinding"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#eligibility-criteria",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#eligibility-criteria",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Eligibility criteria",
    "text": "Eligibility criteria\nNeed to specify which participants are recruited\n\nBalance the advantages and disadvantages of having a highly selected group against those associated with including a wide variety of subjects\nNarrow eligibility criteria tends to increase statistical power as similar subjects are more likely to respond to the treatment in a similar manner, but increases the difficulty of the recruitment.\nWide eligibility criteria tends to increase generalizability of trial results"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#control-group",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#control-group",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Control group",
    "text": "Control group\nTo what reference should the experimental treatment be compared (if any)?\n\nPlacebo control\nActive control\nUncontrolled\nHistorical control\n\nDrugs with no efficacy can seem impressive in uncontrolled trials (e.g. due to placebo effect)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#randomization",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#randomization",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Randomization",
    "text": "Randomization\nRandomization evenly distributes measured and unmeasured factors among intervention groups\n\n\nEach subject has the same chance of being allocated to any treatment group\nThe only systematic difference between the study arms should be the treatment given\nAny differences in results observed at the end of the trial should be due to the effect of the new treatment, and not to any other factors\nAvoids bias and confounding\n\n\n=&gt; Randomization facilitates identification of causal relationships"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#blinding",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#blinding",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Blinding",
    "text": "Blinding\n\nAim: to conceal the trial intervention given to each subject\nSubjects or researchers may have expectations associated with a particular treatment. This may affect the data integrity:\n\nHow patients respond to treatment, regarding both efficacy and safety profile.\nHow the researcher manages or assesses the subject\n\nIt is generally recommended to blind the subject and anyone involved in giving the treatment, or managing or assessing the subject (double-blinded)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Trial design",
    "text": "Trial design\nParallel group design\n\n\nPatients are each randomised to ONE of the treatment arms\nThe results from the 2 (or more) groups are compared at the end of the trial\nUsed when treatments have long-lasting effects\nRecommended approach for phase III trials"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Trial design",
    "text": "Trial design\nCrossover design\n\n\nInstead of randomly allocating subjects to treatment arms, the ordering of treatments is random\nWashout between treatment periods\nEach subject is their own control (eliminates between-subject variability)\nFewer patients needed\nNot suitable to investigate long-term outcomes (e.g., safety)\nOften used in phase I trials that include a control group"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#trial-design-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Trial design",
    "text": "Trial design"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phases",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phases",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phases",
    "text": "Phases\nFour main types of clinical trials"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-i-trial",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-i-trial",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phase I trial",
    "text": "Phase I trial\nTypical objectives\n\nExploratory\nTo determine the pharmacologic and metabolic effects in healthy volunteers\n\nPharmacodynamics (PD): physical or biological measures that show the effect of the new drug on the body\nPharmacokinetics (PK): physical or biological measures that show how the body deals with the new drug.\n\nTo detect the most common side effects"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-i-trial-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-i-trial-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phase I trial",
    "text": "Phase I trial\nKey endpoints: PK parameters\n\nArea under the curve (AUC): quantify total drug exposure\n\\(C_{max}\\) : The highest concentration level\n\\(T_{max}\\) : The time at which \\(C_{max}\\) occurs\n\\(t_{1/2}\\) : terminal half-life, the time it takes for the plasma concentration to decrease by 50% in the final part of the curve, when the drug is being eliminated"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase I trial (NCT01884935)",
    "text": "Example of a phase I trial (NCT01884935)\n\n\nPopulation\n\nPediatric patients with secondary progressive MS\n\nInterventions\n\nNatalizumab 300 mg every 4 weeks for 16 weeks (𝑁=13)\n\nOutcomes:\n\nMaximum plasma concentration (\\(C_{max}\\)) of natalizumab\nMinimum observed concentration (\\(C_{min}\\)) of natalizumab\nTime to maximum observed concentration (\\(T_{max}\\)) of natalizumab\nArea under the concentration-time curve from time zero to infinity (\\(AUC_{inf}\\)) of natalizumab\n…"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase I trial (NCT01884935)",
    "text": "Example of a phase I trial (NCT01884935)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-i-trial-nct01884935-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase I trial (NCT01884935)",
    "text": "Example of a phase I trial (NCT01884935)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-ii-trial",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-ii-trial",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phase II trial",
    "text": "Phase II trial\n\nKey characteristics\n\nAim is to obtain a preliminary estimate of efficacy, and/or to determine the optimal dose\nEmphasis on safety and intermediate outcomes\nRandomization is possible but not essential\n\nExample\n\nA randomized, blinded, parallel-group, phase 2 study exploring the safety, tolerability, and efficacy of multiple regimens of Natalizumab in adult subjects with relapsing MS."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-ii-trial-nct01405820",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-ii-trial-nct01405820",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase II trial (NCT01405820)",
    "text": "Example of a phase II trial (NCT01405820)\n\n\nPopulation\n\nPatients with relapsing-remitting MS\n\nInterventions\n\nNatalizumab 300 mg intravenous (IV) every 4 weeks for 60 weeks (𝑁=54)\nNatalizumab 300 mg subcutaneous (SC)every 4 weeks for 60 weeks (𝑁=45)\nNatalizumab 300 mg IV every 12 weeks for 60 weeks (𝑁=52)\nNatalizumab 300 mg SC every 12 weeks for 60 weeks (𝑁=54)\nNatalizumab 150 mg IV every 12 weeks for 60 weeks (𝑁=47)\nNatalizumab 150 mg SC every 12 weeks for 60 weeks (𝑁=38)\n\nOutcomes\n\nCumulative number of combined unique active lesions"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-iii-trial",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-iii-trial",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phase III trial",
    "text": "Phase III trial\nKey characteristics\n\nAim is to obtain a definitive estimate of efficacy\nInvestigation of clinically relevant outcomes\nRandomization is required\nCommonly implemented to obtain a marketing licence (“pivotal trial”)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase III trial (NCT00027300)",
    "text": "Example of a phase III trial (NCT00027300)\n\nA 2:1 randomized placebo-controlled trial to determine the safety and efficacy of natalizumab in the treatment of individuals with relapsing multiple sclerosis.\n\nPopulation\n\nPatients with relapsing-remitting MS\n\nIntervention(s)\n\nNatalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks (𝑁=627)\n\nComparator(s)\n\nPlacebo, IV infusion, every 4 weeks, for up to 116 weeks (𝑁=315)\n\nOutcomes\n\nCumulative probability of sustained progression of disability at 2 years\nAnnualized rate of relapse"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase III trial (NCT00027300)",
    "text": "Example of a phase III trial (NCT00027300)\nEligibility criteria\n\n“Enrollment was limited to men and women who were between the ages of 18 and 50 years and had a diagnosis of relapsing multiple sclerosis; who had a score of 0 to 5.0 on the Expanded Disability Status Scale (EDSS), a rating that ranges from 0 to 10, with higher scores indicating more severe disease; who had undergone magnetic resonance imaging (MRI) showing lesions consistent with multiple sclerosis; and who had had at least one medically documented relapse within the 12 months before the study began. Patients with disease that was categorized as primary progressive, secondary progressive, or progressive relapsing were excluded. Additional exclusion criteria included the following: a relapse within 50 days before the administration of the first dose of the study drug, treatment with cyclophosphamide or mitoxantrone within the previous year, or treatment with interferon beta, glatiramer acetate, cyclosporine, azathioprine, methotrexate, or intravenous immune globulin within the previous 6 months. Patients who had received treatment with interferon beta, glatiramer acetate, or both for more than six months were also excluded.”\n\n\nRef: Polman CH, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase III trial (NCT00027300)",
    "text": "Example of a phase III trial (NCT00027300)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iii-trial-nct00027300-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase III trial (NCT00027300)",
    "text": "Example of a phase III trial (NCT00027300)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-iv-trial",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#phase-iv-trial",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Phase IV trial",
    "text": "Phase IV trial\nKey characteristics\n\nAim is to study rare side effects or subgroup of patients and “real-world” effectiveness once the new treatment has been adopted into routine clinical practice\nAlso known as post-marketing or surveillance studies\nCommonly involves investigation of patient-reported outcomes"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iv-trial-nct00871780",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iv-trial-nct00871780",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase IV trial (NCT00871780)",
    "text": "Example of a phase IV trial (NCT00871780)\n\nA prospective, open-label, non-randomized clinical trial to determine if natalizumab improves ambulatory measures in relapsing-remitting MS patients.\n\nPopulation\n\nPatients with relapsing-remitting MS\n\nIntervention(s)\n\nNatalizumab 300 mg IV every 4 weeks for 48 weeks (𝑁= 224)\n\nOutcomes\n\nChange From Baseline in the Timed 100-meter Walk Test\nChange From Baseline in the Timed 25-foot Walk Test\nChange From Baseline in Maximum Walking Distance\nChange From Baseline in Expanded Disability Status Scale"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iv-trial-nct00871780-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-iv-trial-nct00871780-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase IV trial (NCT00871780)",
    "text": "Example of a phase IV trial (NCT00871780)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#summary",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#summary",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Summary",
    "text": "Summary"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Estimation of treatment effect",
    "text": "Estimation of treatment effect\nIn randomized clinical trials, we can quantify the treatment effect of drug A (active) versus drug B (control) as follows:"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Estimation of treatment effect",
    "text": "Estimation of treatment effect"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#estimation-of-treatment-effect-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Estimation of treatment effect",
    "text": "Estimation of treatment effect\nIf the data are assumed to be normally distributed, an approximate 95% confidence interval is given by Mean ± (SD/sqrt(n)*1.96)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects\nHypothesis test to evaluate the difference between two (or more) drugs\n\n\\(𝐻_0\\) : Null hypothesis\n\\(𝐻_1\\) : Alternative hypothesis\nAim is to reject \\(𝐻_0\\)\n\nWe assume that \\(𝐻_0\\) is true and subsequently determine the likelihood of the observed data. This results in a p-value (= the probability that an effect as large as that observed, or more if \\(𝐻_0\\) is true)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects\nInterpretation of p-values\n\nP-values &lt; 0.05 provide evidence to reject \\(𝐻_0\\) (and usually indicate that drug A is superior / non-inferior / equivalent to drug B)\nP-values &gt; 0.05 indicate that there is not enough evidence to reject \\(𝐻_0\\) (which does not necessarily mean that \\(𝐻_0\\) is true)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects\nPossible reasons for p&gt;0.05\n\nThere really is no difference\nThere is a real difference, but by chance the sample of subjects did not show this\nThere is a real difference, but the trial had too few subjects, and therefore insufficient power, to detect it.\n\nAbsence of evidence ≠ evidence of absence"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-5",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-5",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-6",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#formal-testing-of-treatment-effects-6",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Formal testing of treatment effects",
    "text": "Formal testing of treatment effects\n\nDetermination of a clinically meaningful difference \\(\\delta\\)\n\nDifferent choice of 𝛿 may affect the sample size calculation\nThe margin \\(\\delta\\) should be based on both statistical reasoning and clinical judgment\n\nPrevious placebo-controlled trials similar to those planned for the new trial (ICH 10 guideline)\nSystematic literature review\nLimits proposed by FDA and/or EMA (e.g., bioequivalence trials)\n\nOne of the most controversial subjects in drug development"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#errors-when-testing-hypotheses",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#errors-when-testing-hypotheses",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Errors when testing hypotheses",
    "text": "Errors when testing hypotheses\n\nThere is a chance that we incorrectly fail to reject \\(𝐻_0\\)\nThere is a chance that we incorrectly reject \\(𝐻_0\\)\nThe chance of error needs to be controlled"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#type-i-error",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#type-i-error",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Type I error",
    "text": "Type I error"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#type-ii-error",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#type-ii-error",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Type II error",
    "text": "Type II error"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#controlling-type-i-and-type-ii-errors",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#controlling-type-i-and-type-ii-errors",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Controlling type I and type II errors",
    "text": "Controlling type I and type II errors"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#confidence-intervals",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#confidence-intervals",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Confidence intervals",
    "text": "Confidence intervals"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sample-size-estimation",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sample-size-estimation",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sample size estimation",
    "text": "Sample size estimation"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sample-size-estimation-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sample-size-estimation-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sample size estimation",
    "text": "Sample size estimation"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Introduction",
    "text": "Introduction\nA biosimilar medicine is a biological medicine that is developed to be highly similar and clinically equivalent to an existing medicine.\n\n\nA biosimilar contains a version of an active substance of an already approved biological medicine, which is referred to as the ‘ reference medicine’.\nSimilarity to the reference medicine must be established based on a comprehensive biosimilar comparability exercise, such that they do not have any clinically meaningful differences from the reference medicine in terms of quality, biological activity, safety, efficacy and immunogenicity."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Introduction",
    "text": "Introduction\nA biosimilar is not regarded as a generic of a biological medicine.\n\n\nThis is mostly because the natural variability and more complex manufacturing of biological medicines do not allow an exact replication of the molecular microheterogeneity.\nConsequently, more studies are needed for regulatory approval of biosimilars than for generics to ensure that minor differences do not affect safety or efficacy."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#introduction-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Introduction",
    "text": "Introduction"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-cdp",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-cdp",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan (CDP)",
    "text": "Clinical Development Plan (CDP)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan",
    "text": "Clinical Development Plan\nPhase I\n\nRandomized to 2-3 arms including the reference product(s)\nNeed to prove the bio-equivalence of PK parameters\nRequires larger sample size than phase I trials of innovative drugs\nBlinded sample size re-assessment is often needed\nRecommend parallel design other than cross-over design from FDA."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#examples",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#examples",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Examples",
    "text": "Examples\n\nHV = Healthy volunteers\n\nThe reference product was studied in 2 separate arms: one US-sourced drug and one EU-sourced drug"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#pharmacokinetic-parameters",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#pharmacokinetic-parameters",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Pharmacokinetic parameters",
    "text": "Pharmacokinetic parameters\nThe trial should demonstrate bio-equivalence for various PK parameters\n\nArea under the blood or plasma concentration–time curve (AUC)\nMaximum concentration Cmax\n…\n\n\nRef: Committee for medicinal products for human use (CHMP). Guideline on the investigation of bioequivalence. London, UK: European Medicines Agency; 2010 Jan. Report No.: CPMP/EWP/QWP/1401/98."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#requirements-for-hypothesis-testing",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#requirements-for-hypothesis-testing",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Requirements for hypothesis testing",
    "text": "Requirements for hypothesis testing\n\nHypothesis testing should be based on the ratio of the population geometric means\nThe 90% confidence interval for the ratio of the test and reference products should be contained within the acceptance interval of 80.00 to 125.00%.\nA margin of clinical equivalence (∆) is chosen by defining the largest difference that is clinically acceptable, so that a difference bigger than this would matter in practice.\nThe data should be transformed prior to analysis using a logarithmic transformation and subsequently be analyzed using ANOVA\n\n\nRef: Committee for medicinal products for human use (CHMP). Guideline on the investigation of bioequivalence. London, UK: European Medicines Agency; 2010 Jan. Report No.: CPMP/EWP/QWP/1401/98."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#hypothesis-test-for-pk-parameters",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#hypothesis-test-for-pk-parameters",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Hypothesis test for PK parameters",
    "text": "Hypothesis test for PK parameters\n\nConsider a PK parameter that follows a log-normal distribution (e.g., \\(C_{max}\\) or AUC)\nWe can assess equivalence by testing the following hypothesis:\n\nNull hypothesis: the drugs are not equivalent\n\\(𝐻_0\\): \\(\\mu_{biosimilar}\\)/\\(\\mu_{reference}\\) ≤ 80% or \\(\\mu_{biosimilar}\\)/\\(\\mu_{reference}\\) ≥125%\nAlternative hypothesis: the drugs are equivalent\n\\(𝐻_1\\): 80% &lt; \\(\\mu_{biosimilar}\\)/\\(\\mu_{reference}\\) &lt;125%\nThe equivalence margins 80% and 125% are set by regulators.\n\nNote: We use the geometric mean for 𝜇 because data are skewed (the geometric mean can be approximated using the median)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#hypothesis-test-for-pk-parameters-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#hypothesis-test-for-pk-parameters-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Hypothesis test for PK parameters",
    "text": "Hypothesis test for PK parameters"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-endpoints",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-endpoints",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple endpoints",
    "text": "Testing of multiple endpoints\nIt is often required to investigate equivalence for more than one primary variable. For example, EMA recommends showing equivalence both for AUC and Cmax\nA decision must be made as to whether it is desirable to\n\nDemonstrate equivalence for all primary endpoints : most common setting\n(also known as “multiple co-primary endpoints”)\nDemonstrate equivalence for at least one of the primary endpoints\n(also known as “multiple primary endpoints”)\n\n\nRef: Sozu T, Sugimoto T, Hamasaki T, Evans SR. Sample Size Determination in Clinical Trials with Multiple Endpoints. Cham: Springer International Publishing; 2015."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple co-primary endpoints",
    "text": "Testing of multiple co-primary endpoints\n\nWhen the trial aims to evaluate the joint effects on all of the \\(m\\) co-primary endpoints\n\nEquivalence has to be shown for all 𝑚 tests\nNo multiplicity adjustment is needed to control the type I error rate because all hypotheses have to be rejected\nThe type II error rate increases as the number of endpoints to be evaluated increases\n\nThe power to reject non-equivalence decreases (for a fixed sample size)\nThe probability that the trial will be “successful” decreases (for a fixed sample size)\n\n\n\n\nRef: Sozu T, Sugimoto T, Hamasaki T, Evans SR. Sample Size Determination in Clinical Trials with Multiple Endpoints. Cham: Springer International Publishing; 2015."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple co-primary endpoints",
    "text": "Testing of multiple co-primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-co-primary-endpoints-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple co-primary endpoints",
    "text": "Testing of multiple co-primary endpoints\nIncrease in sample size can be extreme, especially if\n\nNo correlation exists between the test statistics\nMany tests are carried out\n\nOne possible solution, if the required sample size is not feasible, is to power the study so that at least k out of m tests have to meet the equivalence criterion"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple primary endpoints",
    "text": "Testing of multiple primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple primary endpoints",
    "text": "Testing of multiple primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple primary endpoints",
    "text": "Testing of multiple primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple primary endpoints",
    "text": "Testing of multiple primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#testing-of-multiple-primary-endpoints-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Testing of multiple primary endpoints",
    "text": "Testing of multiple primary endpoints"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Adaptive trial designs",
    "text": "Adaptive trial designs\n\nTrial specifications are often based on preliminary and/or uncertain information\nPerforming a study in a fixed sample size design implies a considerable risk of resulting in a too high or too low sample size.\nIt is desirable to terminate the trial when the treatment seems to be ineffective."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Adaptive trial designs",
    "text": "Adaptive trial designs\nWe can adopt a multi-stage design to\n\nRecruit a portion of the planned sample\nRecalculate the sample size based on the observed variability (without unblinding treatment allocation)\nDetermine whether a test drug is promising enough to warrant further testing"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#adaptive-trial-designs-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Adaptive trial designs",
    "text": "Adaptive trial designs\nSample size re-estimation in bioequivalence studies inflates the type I error according to\n\nThe required sample size\nThe sample size of the internal pilot study\nThe standardized equivalence or non-inferiority margin\n\nThe elevation of the significance level is negligible for most practical situations.\n\nRef: Friede T, Kieser M. Blinded sample size reassessment in non-inferiority and equivalence trials. Statist Med. 2003 Mar 30;22(6):995–1007."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#simulations-for-sample-size-estimation",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#simulations-for-sample-size-estimation",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Simulations for sample size estimation",
    "text": "Simulations for sample size estimation\nEmpirical sample size estimation through simulation\n\nTesting for equivalence on (co-)primary endpoints\nEvaluate the decrease in power due to multiple testing\nEvaluate impact of adaptive design choices\nEmpirically assess type I and type II error as a function of sample size and other parameters\n\n\nRef: Mielke J, Jones B, Jilma B, König F. Sample Size for Multiple Hypothesis Testing in Biosimilar Development. Statistics in Biopharmaceutical Research. 2018 Jan 2;10(1):39–49."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-5",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-5",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-6",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-6",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-7",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-7",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-8",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-8",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-9",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-9",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-10",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-10",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-11",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-11",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-12",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-12",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-13",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#example-of-a-phase-1-biosimilar-study-nct01922336-13",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Example of a phase 1 biosimilar study (NCT01922336)",
    "text": "Example of a phase 1 biosimilar study (NCT01922336)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan of Phase 3",
    "text": "Clinical Development Plan of Phase 3"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan of Phase 3",
    "text": "Clinical Development Plan of Phase 3\nKey differences in sample size estimation\n\n\nChoice of endpoint (preferences may differ between EMA and FDA)\nData distribution: Normal, Binary, Binomial, etc.\nChoice and justification of equivalence margin (e.g., clinical relevance)\n\n\nEquivalence should be demonstrated for all (primary) endpoints for all comparisons between the bio-similar and the (EU-sourced and US-sourced) reference drug"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan of Phase 3",
    "text": "Clinical Development Plan of Phase 3"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan of Phase 3",
    "text": "Clinical Development Plan of Phase 3"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#clinical-development-plan-of-phase-3-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Clinical Development Plan of Phase 3",
    "text": "Clinical Development Plan of Phase 3"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#integral-simulation-for-2-treatment-arms-1-outcome",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#integral-simulation-for-2-treatment-arms-1-outcome",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Integral Simulation for 2 Treatment Arms & 1 Outcome",
    "text": "Integral Simulation for 2 Treatment Arms & 1 Outcome\nA Shiny App"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#apps-structure",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#apps-structure",
    "title": "Introductory Statistics in Clinical Research",
    "section": "App’s Structure",
    "text": "App’s Structure\n\nLANDING PAGE\n\nA pop-up display to choose sample calculation method.\n\nINPUT PANEL\n\nA panel to input parameters needed to calculate the sample. It is changed dynamically depends on the method chosen.\n\nOUTPUT PANEL\n\nDisplays the result of calculation/simulation with the respective input."
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#landing-page",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#landing-page",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Landing Page",
    "text": "Landing Page"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Input Panel",
    "text": "Input Panel"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Input Panel (2)",
    "text": "Input Panel (2)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#input-panel-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Input Panel (3)",
    "text": "Input Panel (3)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#output-panel",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#output-panel",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Output Panel",
    "text": "Output Panel"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#output-panel-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#output-panel-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Output Panel",
    "text": "Output Panel"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#generated-report",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#generated-report",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Generated Report",
    "text": "Generated Report"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#generated-report-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#generated-report-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Generated Report (2)",
    "text": "Generated Report (2)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#randomization-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#randomization-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Randomization",
    "text": "Randomization"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#limitations-of-randomized-trials",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#limitations-of-randomized-trials",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Limitations of randomized trials",
    "text": "Limitations of randomized trials"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#limitations-of-randomized-trials-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#limitations-of-randomized-trials-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Limitations of randomized trials",
    "text": "Limitations of randomized trials"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#the-efficacy-effectiveness-gap",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#the-efficacy-effectiveness-gap",
    "title": "Introductory Statistics in Clinical Research",
    "section": "The efficacy-effectiveness gap",
    "text": "The efficacy-effectiveness gap"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-data-rwd",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-data-rwd",
    "title": "Introductory Statistics in Clinical Research",
    "section": "What is real-world data (RWD)?",
    "text": "What is real-world data (RWD)?"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-data-rwd-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-data-rwd-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "What is real-world data (RWD)?",
    "text": "What is real-world data (RWD)?\nRoutinely collected data relating to a patient’s health status or the delivery of health care from a variety of sources other than traditional clinical trials\nPrimary research data\n\nNew data collection\nE.g., data collected for an ad hoc study or a prospective patient registry\n\nSecondary research data\n\nAnalysis of existing data\nE.g., data from (inter)national databases or electronic healthcare records"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sources of real-world data",
    "text": "Sources of real-world data"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sources of real-world data",
    "text": "Sources of real-world data\nClinical Practice Research Datalink | CPRD\nThe CPRD database contains coded and anonymised EHR data from &gt;2000 primary care practices in UK capturing information on:\n\nDemographic characteristics\nDiagnoses and symptoms\nDrug exposures\nVaccination history\nLaboratory tests\nReferrals to hospital and specialist care"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sources of real-world data",
    "text": "Sources of real-world data"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#sources-of-real-world-data-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Sources of real-world data",
    "text": "Sources of real-world data"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-evidence-rwe",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#what-is-real-world-evidence-rwe",
    "title": "Introductory Statistics in Clinical Research",
    "section": "What is real-world evidence (RWE)?",
    "text": "What is real-world evidence (RWE)?\n\nInformation derived from the analysis of RWD\n\nObservational studies\nAdministrative (e.g., claims) databases\nRegistries\nWearable devices\n…\n\nInformation derived from combining clinical trial data and RWD\n\nIncorporation of historical controls\nIndirect treatment comparisons"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#real-world-evidence-studies",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#real-world-evidence-studies",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Real-world evidence studies",
    "text": "Real-world evidence studies\nWell-designed, well-executed, and well reported nonrandomized observational studies are a critical component of the body of evidence\n\nRWE studies may help to identify how new drugs are utilized and impacted under routine prescribing practice\nResults of RCTs and non-randomised studies do not inevitably differ [ref, ref, ref]\n(especially if statistical analyse target the same estimands)\nHigh degree of reproducibility for RWE studies with good methodological transparency [ref]"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#use-of-real-world-evidence",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#use-of-real-world-evidence",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Use of real-world evidence",
    "text": "Use of real-world evidence"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-prospective-cohort-studies",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-prospective-cohort-studies",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE from prospective cohort studies",
    "text": "RWE from prospective cohort studies"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-registry-based-studies",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-registry-based-studies",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE from registry-based studies",
    "text": "RWE from registry-based studies"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-pragmatic-trials",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-from-pragmatic-trials",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE from pragmatic trials",
    "text": "RWE from pragmatic trials"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#leveraging-rwd-in-clinical-trials",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#leveraging-rwd-in-clinical-trials",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Leveraging RWD in clinical trials",
    "text": "Leveraging RWD in clinical trials\nIncorporation of historical data during the design and analysis of clinical trials may help to:\n\nLower both cost and trial duration\nFacilitate participant recruitment\nAddress ethical barriers (e.g. pediatric studies)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE studies – what is the catch?",
    "text": "RWE studies – what is the catch?\nThe analysis of real-world data is prone to various sources of bias.\n\nThe Achilles heel of observational studies is error due to imbalance in unobserved variables"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-1",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-1",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE studies – what is the catch?",
    "text": "RWE studies – what is the catch?"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-2",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-2",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE studies – what is the catch?",
    "text": "RWE studies – what is the catch?\nMissing data\n\nKey variables and outcomes are not always measured or collected\nLack of data may be informative\nRight censoring, e.g., loss to follow-up\nInterval censoring, e.g., when observing an AE requires follow-ups or inspections\nLeft censoring\nLack of time zero data (especially when making secondary use of RWD)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-3",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-3",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE studies – what is the catch?",
    "text": "RWE studies – what is the catch?\nHeterogeneity\n\nRoutine clinical practice (e.g., treatment options, dosage)\nVariable & outcome definitions\nVisit schedules and patient follow-up\nQuality and completeness of relevant data sources\nAnalysis methods [ref] (e.g. when combining data across multiple registries)"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-4",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#rwe-studies-what-is-the-catch-4",
    "title": "Introductory Statistics in Clinical Research",
    "section": "RWE studies – what is the catch?",
    "text": "RWE studies – what is the catch?"
  },
  {
    "objectID": "slides/Workshop clinical trials/Workshop clinical trials.html#appraising-the-quality-of-rwe",
    "href": "slides/Workshop clinical trials/Workshop clinical trials.html#appraising-the-quality-of-rwe",
    "title": "Introductory Statistics in Clinical Research",
    "section": "Appraising the quality of RWE",
    "text": "Appraising the quality of RWE"
  }
]